Last edition
News about "Akums "
Akums Receives First UK MHRA Approval for Rivaroxaban
Rivaroxaban is an oral anticoagulant prescribed for the prevention and treatment of thromboembolic disorders, including Non-Valvular Atrial Fibrillation (NVAF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE) and clinically relevant cardiovascular risk reduction.
Akums | 10/02/2026 | By News Bureau
Akums Signs MoU with Sharda University Agra to Advance Pharma Research
Akums Drugs & Pharmaceuticals has entered into a Memorandum of Understanding (MoU) with Sharda University, Agra, to collaborate on pharmaceutical research, technology transfer, and skill development, with an emphasis on strengthening the linkage between academic research and industrial application.
Akums | 29/12/2025 | By Darshana
Akums Launches Enhanced Gabapentin ER Formulation for PHN
Akums Drugs and Pharmaceutical has introduced an enhanced Gabapentin Extended-Release (ER) formulation powered by its RetenEx technology for the management of postherpetic neuralgia (PHN), a chronic neuropathic pain condition that affects around 10-20 percent of patients following a shingles outbreak.
Akums | 15/12/2025 | By News Bureau | 100
Akums's Hormonal Plant Gets EAEU GMP Nod, Expands into Eurasia
Akums’s Hormonal Plant receives EAEU GMP certification for oral hormonal tablets, enabling entry into Eurasian markets with therapies for women’s health, HRT and endocrine care.
Akums | 09/09/2025 | By Dineshwori | 256
Akums Becomes First Indian CDMO to Receive DCGI Approval for Innovative Glaucoma Treatment
Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5 percent of the global burden.
Akums | 01/04/2025 | By Abha | 425
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy